Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK4 | O96013 | 1/20 | 0.41 |
| ▸ | MAP3K14 | Q99558 | 17/20 | 0.39 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1614095 | 0.90 | PAK4 (0.43) | PAK4MAP3K14PRKD1NPC1RAB9A | |
| SCHEMBL1613906 | 0.88 | PAK4 (0.42) | PAK4MAP3K14PRKD1NPC1RAB9A | |
| SCHEMBL1612464 | 0.88 | PAK4 (0.42) | PAK4MAP3K14PRKD1NPC1RAB9A | |
| SCHEMBL1613216 | 0.84 | MAP3K14 (0.38) | PAK4MAP3K14PRKD1NPC1RAB9A | |
| SCHEMBL12742516 | 0.84 | MAP4K1 (0.36) | — | |
| SCHEMBL1614014 | 0.81 | MAP3K14 (0.40) | PAK4MAP3K14PRKD1NPC1RAB9A | |
| SCHEMBL1614170 | 0.81 | MAP3K14 (0.37) | PAK4MAP3K14PRKD1NPC1RAB9A | |
| SCHEMBL1613420 | 0.80 | PAK4 (0.38) | PAK4MAP3K14PRKD1NPC1RAB9A | |
| SCHEMBL1613968 | 0.80 | PAK4 (0.38) | PAK4MAP3K14PRKD1NPC1RAB9A | |
| SCHEMBL13575081 | 0.80 | NPC1 (0.38) | PAK4MAP3K14NPC1RAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2315751-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | Amgen Inc. (US) | 2011-05-04 | — | — | EP | disclosed |
| US-20110086834-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | AMGEN INC. (US) | 2011-04-14 | — | — | US | disclosed |
| US-20110086834-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | AMGEN INC. (US) | 2011-04-14 | — | — | US | disclosed |
| WO-2009158011-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | AMGEN INC. (US) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009158011-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | AMGEN INC. (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086834-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | NFKBIA, MAP3K1, MAP3K2 | PAK4 323/4885MAP3K14 17/4885PRKD1 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.